First Human Trial to Evaluate QR-313 for Dystrophic Epidermolysis Bullosa Initiated

While there are currently no approved treatments for the rare skin disease, there are therapies in development, such as ProQR’s RNA therapy, QR-313, which is now being evaluated in its first human clinical trial, dubbed “WINGS.”